Icecure Medical Ltd
ICCM
Company Profile
Business description
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
Contact
7 Haeshel Street
Southern Industrial Park
PO Box 3163
Caesarea3079504
ISRT: +972 46230333
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
66
Stocks News & Analysis
stocks
ASX healthcare leader sees further cuts to fair value
Fiercer competition expected to squeeze margins.
stocks
Avoid this overpriced ASX share
This ASX share is 84% overvalued and lacks a sustainable competitive advantage.
stocks
Markets brief: How will AI affect economic moats? Morningstar’s take on the new paradigm
A broad assessment of AI’s threats and opportunities leads to moat ratings changes for more than three dozen companies.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,970.20 | 14.10 | 0.16% |
| CAC 40 | 8,052.43 | 58.94 | 0.74% |
| DAX 40 | 23,968.63 | 559.26 | 2.39% |
| Dow JONES (US) | 47,706.51 | 34.29 | -0.07% |
| FTSE 100 | 10,409.53 | 160.01 | 1.56% |
| HKSE | 25,959.90 | 202.61 | 0.79% |
| NASDAQ | 22,697.10 | 1.16 | 0.01% |
| Nikkei 225 | 55,259.44 | 1,011.05 | 1.86% |
| NZX 50 Index | 13,262.67 | 168.30 | 1.29% |
| S&P 500 | 6,781.48 | 14.51 | -0.21% |
| S&P/ASX 200 | 8,739.10 | 15.00 | 0.17% |
| SSE Composite Index | 4,123.14 | 26.54 | 0.65% |